Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir ; volume:20 ; number:1 ; day:13 ; month:3 ; year:2023 ; pages:1-11 ; date:12.2023
AIDS research and therapy ; 20, Heft 1 (13.3.2023), 1-11, 12.2023
- Urheber
-
Mulindwa, Frank
Castelnuovo, Barbara
Brusselaers, Nele
Bollinger, Robert
Rhein, Joshua
Edrisa, Mutebi
Buzibye, Allan
Amutuhaire, Willington
Yendewa, George
Nabaggala, Sarah
Odongpiny, Eva Laker Agnes
Kiguba, Ronald
Nakawooza, Aisha
Dujanga, Simon
Nabwana, Martin
Schwarz, Jean-Marc
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12981-023-00510-6
- URN
-
urn:nbn:de:101:1-2408070919030.961454761132
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mulindwa, Frank
- Castelnuovo, Barbara
- Brusselaers, Nele
- Bollinger, Robert
- Rhein, Joshua
- Edrisa, Mutebi
- Buzibye, Allan
- Amutuhaire, Willington
- Yendewa, George
- Nabaggala, Sarah
- Odongpiny, Eva Laker Agnes
- Kiguba, Ronald
- Nakawooza, Aisha
- Dujanga, Simon
- Nabwana, Martin
- Schwarz, Jean-Marc
- SpringerLink (Online service)
Ähnliche Objekte (12)
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Creation of a long-acting nanoformulated dolutegravir
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Addendum zum Auftrag A17-11
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Creation of a long-acting nanoformulated dolutegravir
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Addendum zum Auftrag A17-11
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Creation of a long-acting nanoformulated dolutegravir
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment